A Double-blind Randomized Placebo-controlled Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decreased Exercise Tolerance

Brief description of study

The purpose of this study is to find out more about the effects of an investigational drug called omecamtiv mecarbil (OM), when given to people who have heart failure. OM is also known as AMG 423. OM is an investigational drug that has been designed to increase the heart’s ability to pump. However, its effectiveness has not yet been proven. This study will measure the effect of OM on exercise capacity and activity level and evaluate the safety of OM. “Investigational” means that it has not been approved by the Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.


Clinical Study Identifier: s19-00205
ClinicalTrials.gov Identifier: NCT03759392
Principal Investigator: Stuart D. Katz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.